T2017-002, A TACL Phase 1/2 Study of PO Ixazomib in Combination with Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Study ID: STU-2019-0546
Summary
Please refer to Sections 10.1, 10.1.1, 10.1.2, and 10.2 of the protocol.